Shu Xian Lee, Benita Yong Wu, K. Suter, Matthew Scott Lokant, A. Ward, Amy Spigelmyer, Jesse Martin Thompson, R. Demkowicz, Catessa A Howard, P. Rocco LaSala, Rebecca Reece
{"title":"Clinical Outcomes with Implementation of Accelerate Pheno™ Blood Culture Detection System for Gram-Negative Bacteremia","authors":"Shu Xian Lee, Benita Yong Wu, K. Suter, Matthew Scott Lokant, A. Ward, Amy Spigelmyer, Jesse Martin Thompson, R. Demkowicz, Catessa A Howard, P. Rocco LaSala, Rebecca Reece","doi":"10.11648/j.ajlm.20230803.11","DOIUrl":null,"url":null,"abstract":": Delayed treatment in bacteremia increases patient morbidity and healthcare costs. Accelerate Pheno™ Blood Culture Detection System (AXDX) is a novel diagnostic technology for the rapid detection of gram-negative bacteremia. Studies have shown accurate and faster time to speciation and sensitivity (TTSS) by AXDX compared to conventional modality. However, however, our study further examined the direct impact of AXDX on clinical outcomes and cost. Our retrospective study consisted of 178 patients at least 18 years old admitted to our academic medical institution with gram-negative","PeriodicalId":320526,"journal":{"name":"American Journal of Laboratory Medicine","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/j.ajlm.20230803.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
: Delayed treatment in bacteremia increases patient morbidity and healthcare costs. Accelerate Pheno™ Blood Culture Detection System (AXDX) is a novel diagnostic technology for the rapid detection of gram-negative bacteremia. Studies have shown accurate and faster time to speciation and sensitivity (TTSS) by AXDX compared to conventional modality. However, however, our study further examined the direct impact of AXDX on clinical outcomes and cost. Our retrospective study consisted of 178 patients at least 18 years old admitted to our academic medical institution with gram-negative
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
